Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: The invention provides an antibody that specifically binds to a 5? to 3? exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5? to 3? exonuclease activity of a DNA polymerase, or a fragment thereof.

Abstract: The present invention relates to a novel use of an antibody biding specifically to the N-terminus of lysyl-tRNA synthetase and, more particularly, to a pharmaceutical composition comprising an antibody biding specifically to an epitope including the sequence of SEQ ID NO: 117 in the N-terminal domain of lysyl-tRNA synthetase (KRS) or a functional fragment thereof as an effective ingredient for preventing and treating an immune cell migration-related disease. A KRS N-terminus-specific antibody provided by the present invention can regulate the migration of immune cells, thereby exhibiting very remarkable effects in the prevention, alleviation, and treatment of immune cell migration-related diseases.

Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.

Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).

Abstract: The present invention provides methods for reducing or eliminating a patient's need for lipoprotein apheresis therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody. The methods of the present invention are useful for treating patients with hyperlipidemia and related conditions who are currently being treated with a therapeutic regimen comprising lipoprotein apheresis (e.g., LDL apheresis or Lp(a) apheresis).

Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.

Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.

Abstract: The present invention relates antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14), competing with LIGHT binding to cellular receptors Herpes virus entry mediator (HVEM) and lymphotoxin beta receptor, and the use of said antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.

Abstract: The present invention provides anti-MASP-1 (mannan-binding lectin (MBL)-associated serine protease 1) antibodies and methods of using the same. In some embodiments, an anti-MASP-1 antibody of the invention binds to MASP-1 but does not bind to MASP-3. The invention also provides nucleic acids comprising a nucleotide sequence encoding an anti-MASP-1 antibody of the present invention. The invention further provides pharmaceutical compositions comprising an anti-MASP-1 antibody of the present invention and a pharmaceutically acceptable carrier.

Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3.

Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.

Abstract: The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for fibroblast activation protein (FAP). In another embodiment, the treatment includes administering a cell genetically modified to express a T cell receptor (TCR) specific for an activated fibroblast.

Abstract: In one aspect, antibodies that specifically bind to a human BACE1 protein are provided herein. In some embodiments, the antibodies contain modifications that reduce effector function, extend serum stability or serum half-life, or promote heterodimerization. In other aspects, bispecific antibodies and pharmaceutical compositions comprising antibodies that bind to human BACE1 protein are provided herein. Methods for inhibiting amyloid-? formation and/or aggregation, inhibiting amyloid plaque formation, and treating neurodegenerative diseases are also provided herein.

Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.

Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.